Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that ...

In our best practices blog, we explore how lateral flow assay design affects test performance. Read on to gain a deeper understanding of the development process, enabling you to streamline the ...

The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provide quick results while delivering expected performance and ...

Since biological therapeutics are derived from living organisms, their manufacture and validation presents difficulties not encountered during traditional small molecule drug development. Despite the ...

The company said it is prepared to rapidly deploy a Bundibugyo virus Ebola test if outbreak conditions require expanded ...

The COVID-19 pandemic and geopolitical conflict in Eastern Europe have done irreparable damage to the underpinnings of the clinical diagnostic industry. These events significantly impacted the supply ...

As AI accelerates target discovery and pushes more candidates toward the bench, assay development and transfer have become critical bottlenecks. Teams relying on one-factor-at-a-time (OFAT) workflows ...

Cancer research increasingly depends on assays that can keep pace with biological complexity, interrogating key mechanisms such as signaling pathways, enzyme activity, and cell metabolism. 1,2 As ...

This article and associated images are based on a poster originally authored by Linda Kitching, Maxime Couturier, Jonathan Tart, Erik Elebring, Marcel Taillefer, Claudio Pathe, Giulia Bonetto, ...